gip and glp-1 agonist The activity of for Type 2 Diabetes and Obesity GIPR/GLP-1R dual agonist therapies for
Description
doi: 10.1210/jc.2010-2081
Nature 518 , 197206 (2015)
user base of anti-obesity medications (such as GLP-1RAs) to be c.5m users and expects this to grow to c.24m by 2035, while Goldman Sachs5 projects c.15m U.S
This series is coordinated by Caroline Wellbery, MD, associate deputy editor
Providers are encouraged to exercise their own clinical judgment based on each individual patients health care needs.
Kadouh H, Chedid V, Halawi H, et al
